| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥317.38B | ¥312.02B | +1.7% |
| Cost of Sales | ¥217.26B | ¥217.68B | -0.2% |
| Gross Profit | ¥100.12B | ¥94.34B | +6.1% |
| SG&A Expenses | ¥84.78B | ¥80.88B | +4.8% |
| Operating Income | ¥15.34B | ¥13.46B | +14.0% |
| Non-operating Income | ¥2.52B | ¥2.61B | -3.4% |
| Non-operating Expenses | ¥9.62B | ¥11.57B | -16.9% |
| Ordinary Income | ¥8.23B | ¥4.49B | +83.3% |
| Profit Before Tax | ¥12.45B | ¥4.05B | +207.3% |
| Income Tax Expense | ¥5.81B | ¥3.24B | +79.6% |
| Net Income | ¥6.63B | ¥813M | +715.9% |
| Net Income Attributable to Owners | ¥5.91B | ¥129M | +4477.5% |
| Total Comprehensive Income | ¥-11.25B | ¥30.72B | -136.6% |
| Depreciation & Amortization | ¥30.15B | ¥30.24B | -0.3% |
| Interest Expense | ¥4.47B | ¥3.72B | +20.3% |
| Basic EPS | ¥36.21 | ¥0.79 | +4483.5% |
| Diluted EPS | ¥32.08 | ¥0.70 | +4482.9% |
| Dividend Per Share | ¥12.00 | ¥12.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥580.48B | ¥574.42B | +¥6.06B |
| Cash and Deposits | ¥109.97B | ¥106.67B | +¥3.30B |
| Accounts Receivable | ¥152.67B | ¥166.86B | ¥-14.19B |
| Inventories | ¥176.95B | ¥170.86B | +¥6.09B |
| Non-current Assets | ¥573.15B | ¥596.14B | ¥-23.00B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥16.87B | ¥15.03B | +¥1.84B |
| Investing Cash Flow | ¥-13.69B | ¥-54.80B | +¥41.11B |
| Financing Cash Flow | ¥1.62B | ¥23.34B | ¥-21.73B |
| Free Cash Flow | ¥3.18B | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | 1.9% |
| Gross Profit Margin | 31.5% |
| Current Ratio | 149.7% |
| Quick Ratio | 104.1% |
| Debt-to-Equity Ratio | 2.87x |
| Interest Coverage Ratio | 3.43x |
| EBITDA Margin | 14.3% |
| Effective Tax Rate | 46.7% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +1.7% |
| Operating Income YoY Change | +14.0% |
| Ordinary Income YoY Change | +83.3% |
| Net Income Attributable to Owners YoY Change | -98.7% |
| Total Comprehensive Income YoY Change | -7.0% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 171.46M shares |
| Treasury Stock | 8.36M shares |
| Average Shares Outstanding | 163.10M shares |
| Book Value Per Share | ¥1,825.58 |
| EBITDA | ¥45.49B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥12.00 |
| Year-End Dividend | ¥13.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| MedicalTreatmentRelated | ¥256.32B | ¥23.95B |
| MedicineRelated | ¥66.67B | ¥4.91B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥677.00B |
| Operating Income Forecast | ¥37.00B |
| Ordinary Income Forecast | ¥24.20B |
| Net Income Attributable to Owners Forecast | ¥12.95B |
| Basic EPS Forecast | ¥79.40 |
| Dividend Per Share Forecast | ¥18.00 |
| Property, Plant & Equipment | ¥484.80B | ¥503.83B | ¥-19.03B |
| Intangible Assets | ¥32.24B | ¥35.51B | ¥-3.27B |
| Goodwill | ¥12.13B | ¥14.10B | ¥-1.97B |
| Investment Securities | ¥13.78B | ¥15.29B | ¥-1.51B |
| Total Assets | ¥1.15T | ¥1.17T | ¥-16.94B |
| Current Liabilities | ¥387.81B | ¥350.55B | +¥37.26B |
| Accounts Payable | ¥82.59B | ¥83.80B | ¥-1.21B |
| Short-term Loans | ¥155.26B | ¥156.17B | ¥-917M |
| Non-current Liabilities | ¥468.08B | ¥508.40B | ¥-40.32B |
| Long-term Loans | ¥299.41B | ¥309.99B | ¥-10.57B |
| Total Liabilities | ¥855.88B | ¥858.94B | ¥-3.06B |
| Total Equity | ¥297.74B | ¥311.62B | ¥-13.88B |
| Capital Stock | ¥84.40B | ¥84.40B | ¥0 |
| Capital Surplus | ¥1M | - | - |
| Retained Earnings | ¥108.56B | ¥104.78B | +¥3.78B |
| Treasury Stock | ¥-10.75B | ¥-10.75B | ¥-1M |
| Owners' Equity | ¥238.94B | ¥252.44B | ¥-13.50B |
| Working Capital | ¥192.68B | - | - |